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Summary A retrospective analysis was performed of 18 patients with primary malignant germ cell tumours of
the mediastinum treated with platinum-based chemotherapy between 1977 and 1990. All seven patients with
pure seminoma were treated initially with chemotherapy and four of these patients received additional
mediastinal radiotherapy. Only one patient relapsed; his initial therapy had included radiotherapy and
single-agent carboplatin and he was successfully salvaged with combination chemotherapy. With a follow-up
of 11 to 117 months (median 41 months) all seven patients with seminoma remain alive and disease free giving
an overall survival of 100%. Eleven patients had malignant non seminoma; following chemotherapy eight of
these had elective surgical resection of residual mediastinal masses. Complete remission was achieved in nine
(82%) patients, however, one of these patients died from bleomycin pneumonitis. With a follow-up of 12 to
113 months (median 55 months) eight of 11 (73%) patients with malignant mediastinal teratoma remain alive
and disease free.
Although rare, primary malignant germ cell tumours of the
mediastinum are a clinically important group of tumours
which account for 5 to 13% of all malignant mediastinal
tumours (Oberman & Libke, 1964; Cox, 1975; Raghaven,
1991). It is estimated that 1 to 4% of all primary malignant
germ cell tumours arise from an extragonadal site (Collins &
Pugh, 1964) of which the anterior mediastinum is the second
most common. Despite having a spectrum of histology
similar to primary gonadal tumours it has been reported that
they have a worse prognosis compared to metastatic germ
cell tumours of gonadal origin (Kuzur et al., 1982; Feun et
al., 1980; Toner et al., 1991; Vugrin et al., 1981). This
certainly appears to be true for mediastinal teratoma, how-
ever, most reports now show that good results can be
obtained from using platinum based chemotherapy for
primary mediastinal seminoma (Israel et al., 1985). The cur-
rent prognosis of mediastinal teratoma has been difficult to
assess because many reported series extend back over a long
time period. We have restricted this analysis to the era of
platinum based chemotherapy and have assessed all patients
referred to the Testicular Tumour Unit at the Royal Mars-
den Hospital with primary malignant germ cell tumours of
the mediastinum between 1977 and 1989. Results on several
of these patients have been reported elsewhere (Horwich et
al., 1986; Kay et al., 1987).
Patients details and methods
The study was a retrospective review of all case notes of
patients with the diagnosis of primary malignant mediastinal
germ cell tumour who had received platinum based chemo-
therapy at the RMH between 1977 and 1989. The criteria for
inclusion were that patients had to present with a mass in the
anterior mediastinum, have histology or marker evidence of a
germ cell tumour; and have normal testes on initial and
subsequent examinations. The distinction from occult tes-
ticular primary cancer was based on the location of the mass
within the anterior mediastinum, since this is an extremely
uncommon metastatic site from overt testicular primaries.
Patients who had received previous chemotherapy were ex-
cluded. Four patients with seminoma and six with non-
seminoma were reported previously (Horwich et al., 1986),
but the follow-up data has been extended.
Patient characteristics
The patients were all male and had a median age of 33 years
(range: 21 to 64 years). A biopsy of the tumour was obtained
prior to treatment in all but one patient, seven patients had
pure seminoma and 11 had malignant teratoma. The one
patient who did not have a biopsy was an 18 year old with a
larger anterior mediastinal mass and an increased serum
alphafetoprotein of 2,057 Iu 1-'. The most common presen-
ting clinical features were dyspnoea (50%), cough (50%),
chest pain (67%) and constitutional symptoms (lethargy,
malaise, anorexia or weight loss) (39%). The tumours were
arising in the anterior mediastinum and were very extensive
in all patients. Direct invasion of tumour into the anterior
chest wall was present in four patients with seminoma.
Metastases outside the mediastinum were found in three
patients (27%) with teratoma and four patients (57%) with
seminoma. The sites of metastases were axilla or neck nodes
(five patients), lung (two patients), bone (one patient) and
upper para-aortic nodes (one patient).
Investigations
On referral to the Royal Marsden Hospital all patients had a
chest X-Ray, full blood count, liver function and sequential
measurement of serum alphafetoprotein (AFP) and Beta
subunit of human chorionic gonadotrophin (HCG). Most
had a CT scan of the chest (15 patients) and abdomen (14
patients). An ultrasound scan of the testes was carried out in
eight patients. Other investigations such as lymphangio-
graphy (four patients), whole lung tomography (three
patients), bone scintigraphy (two patients) or abdominal
ultrasound were performed where indicated or when CT
scanning was unavailable.
Previous treatment
Three patients had received some treatment prior to referral
(surgery two, radiotherapy one). Two of these patients had
persistent tumour after this initial treatment and one patient
had relapsed after an apparent complete response.
Treatment
Details of treatment given to each patient are outlined in
Tables I and II. The usual management for patients with
seminoma was single agent carboplatin (Horwich et al., 1989)
(five patients) followed by mediastinal radiotherapy to a total
midplane dose of 30 Gy in 15 fractions over 3 weeks. Other
chemotherapy protocols used for seminoma were BEP (Peck-
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ham et al., 1983) (two patients) and PVB (Einhorn &
Donohue, 1977) (one patient). The chemotherapy protocols
used for teratoma were PVB (two patients), BEP (one
patient), BEVIP (Peckham et al., 1988) (two patients) and a
combination of these protocols (two patients). More recently
an intensive schedule CBOP-BEP, based on the BOP-BEP
protocol (Horwich et al., 1989) developed for use in poor
prognosis metastatic malignant teratoma, has been used. The
modification was the incorporation of carboplatin with cis-
platin to increase platinum dose intensity in the first phase of
treatment (Table III). Carboplatin was added to weeks 2 and
4 of the standard BOP-BEP schedule to a dose designed to
achieve a serum concentration x time of 2 mg, ml-' min
(Calvert et al., 1989) CBOP-BEP has been given to four
patients with mediastinal teratoma and BOP-BEP was given
to one patient with mediastinal seminoma who relapsed after
treatment with single agent carboplatin. Most of the patients
with teratoma (eight patients) had surgical resection of
residual mediastinal masses after chemotherapy. Complete
response was defined either by radiological resolution to an
opacity less than 2 cm in diameter, or by complete excision
of a residual mass which did not contain any persisting
undifferentiated tumour.
Results
All patients with seminoma responded to chemotherapy,
however, one patient relapsed with metastases involving bone
and para-aortic lymph nodes 7 months after receiving car-
boplatin. This patient was successfully salvaged using BOP-
BEP chemotherapy. At present all seven patients with
seminoma remain alive and disease free giving an overall
survival of 100%.
A complete response to chemotherapy and surgery was
obtained in nine of the 11 patients with teratoma (CR 82%),
however, one patient who obtained a complete response died
from bleomycin pneumonitis. The remaining eight patients
remain alive and disease free giving an overall survival of
75%. The two patients who achieved a partial response died
from progressive malignancy 5 and 8 months after treatment.


















Cisplatin 40 mg m-2 over 24 h
Carboplatin AUC = 2 mg ml-' x min over 1 h
Vincristine 2 mg
Bleomycin 75 u infusion (15 u per day x 5)
1 2 3 4
A B A B
Bleomycin 15 u + Vincristine 2 mg
BEP x 3 Bleomycin = 15 u per week
Etoposide (E) = 100mg m-2 day-' x 5 days
Cisplatin (P) = 20 mg m-2 day-' x 5 days
PE Cycle = 21 days
AUC = calculated serum concentration x time (Calvertetal., 1989).
The four patients given CBOP-BEP chemotherapy obtained a
complete response and remain in remission while the two
treatment failures occurred where combination cisplatinum
chemotherapy of lesser intensity was used. Treatment results
are summarised in Table IV.
Of the patients with seminoma, five had a significant
residual mass after chemotherapy and four of these patients
have persistent soft tissue masses which remained static on
follow-up CT scans. In the nine patients with teratoma who
obtained a complete remission persistent residual masses
remained after chemotherapy. Surgical resection of the
residual mass was undertaken for seven of these patients, the
histology showed necrosis and fibrosis in six patients and
mature teratoma in one patient. The two surviving patients
with teratoma who did not have further surgery continue to
have non progressive soft tissue masses within the media-
stinum on CT scan. One patient with teratoma who had only
a partial response to chemotherapy had surgical resection of
his residual mediastinal mass, with persistant malignant
teratoma (MTT) seen in the histology.
Table I Details of patients having mediastinal seminoma
Followup
Age Radiotherapy Chemotherapy survival
No. yrs Histology axFP PHCG (mediastinal) (cycles) Outcome (months)
12 36 Seminoma 6 6 30 Gy Carboplatin (4) CR 23 +
13 33 Seminoma 5 5 30Gy BEP (4) CR 84+
14 27 Seminoma 5 83 Nila Carboplatin (6) Relapse 41 +a
15 37 Seminoma - - Nil Carboplatin (6) CR 42+
16 39 Seminoma 5 3 Nil PVB (4) CR 117+
17 38 Seminoma 4 11 30 Gy Carboplatin (4) CR 11 +
18 64 Seminoma 7 35 30 Gy Carboplatin (4) CR 13+
aRelapse 7 months post carboplatin: now in CR following BOP-BEP. This patient was given mediastinal
radiotherapy (40 Gy) prior to referral.
Table II Details of patients with mediastinal teratoma
Followup
Age Chemotherapy survival
No. yrs Histology ccFP PHCG (cycles) Surgery Outcome (months)
1 37 MTU 28,790 2 CBOP-BEPd Yes CR 37+
2 34 MTU 7,706 2 CBOP-BEP Yes CR 26+
3 24 MTU 24,000 2 BEPb Yes CR 92+
4 21 Nil 2,057 2 CBOP-BEP Yes CR 12+
5 29 MTU 9,168 2 CBOP-BEP Yes CR 12+
6 33 MTU 28,000 10 BEVIPb Yes CR 113+
7 37 Yolk Sac 20,000 3 BEVIPb Yes Dieda 4
8 26 Yolk Sac 9,800 2 PVB/BEPC Nil CR 113+
9 29 MTI 2,900 3 PVBb Nil Died 5
10 30 MTT 5 22,700 BEVIP/BEPb Yes Died 8
1 1 27 Mixed 25 3 PVBC Nil CR 72+
MTU/Seminoma
aBleomycin pneumonitis, patient in CR at time of death. b6 cycles. C4 cycles. dsee Table III.1100 W.J. CHILDS et al.
Substantially elevated tumour markers (Table II) were
present in ten patients with teratoma at the time of referral;
the one patient with no significant elevation of markers had
extensive surgical resection ofhis mediastinal tumour prior to
referral. Normalisation of the markers had occurred in four
patients following chemotherapy and in four patients follow-
ing both chemotherapy and surgery. Marked reduction of the
marker levels was seen in the two patients obtaining a partial
response but they never fell to normal. A modest elevation of
BetaHCG (Table I) was measured in two patients with
seminoma which returned to normal following chemo-
therapy.
It has been suggested that there is an association between
mediastinal germ cell tumour and haematological neoplasia
(Nichols et al., 1990b), however, none of our patients have
shown any clinical evidence of this.
Discussion
This study confirms the excellent results that can be obtained
with platinum-based chemotherapy for mediastinal semi-
noma; these tumours should clearly be distinguished from
malignant teratoma or germ cell tumours having non-
seminomatous elements where most reports have indicated a
35 to 60% survival. For mediastinal seminoma (Table IV) an
overall survival in excess of 80% can be expected with the
use of chemotherapy with or without radiotherapy (Horwich
& Peckham, 1986; McLeod et al., 1988; Kiffer & Sandeman,
1989; Logothetis et al., 1985; Giaccone et al., 1991; Kersh et
al., 1987). Based on this study and a recent report on the
treatment for metastatic seminoma (Horwich et al., 1989) it
appears that single agent carboplatin may be an appropriate
first line treatment for patients with primary mediastinal
Table IV Reported results for treatment ofmediastinal seminoma
Follow-up
No. of Survival median
Author/Reference patients (%) (range) Treatment
McLeod et al., 1988 2 2 (100) 21-44 CT & S-2
CT(VAB VV)
Kiffer et al., 1989 4 2 (50) (43-63) RT-3
CT(PVB)-l
Logothetis et al., 1985 4 4 (100) - CT-4
CT(PVB or
CISCA)
Giaccone et al., 1989 9 6 (66) 49 CT(PVB)-8
(25- 106) RT-I
Kersh et al., 1987 13 13 (100) RT-12
CT-I
Horwich et al. 7 7 (100) 41 (11-117) CT ± RT
(current series) (see text)
Total 39 34 (87)
CT = Chemotherapy ( )-denotes type of chemotherapy where stated; RT =
Radiotherapy; S = Surgery; VABW = VAB alternating withetoposide (VP16-213)
and vincristine; PVB = Cisplatin, bleomycin and vincristine; CISCA = Cisplatin,
cyclophosphamide and doxorubicin.
Table V Reported results for treatment of mediastinal teratoma
Follow-up
No. of Survival median
Author/Reference patients (%) (range) Treatment
McLeod et al., 1988 7 3 (43) (1-37) CT-7
S-3 CT (VAB VV
or VAB-W)




Parker et al., 1986 8 5 (63) 69 CT & S-6
(37-160) CT-2
Logothetis et al., 1985 20 7 (35) CT-20
Giaccone et al., 1989 6 3 (50) (26-70) CT-6 (PVB or
BEP)
Kersh et al., 1987 14 3 (21) - CT-most
RT-14
Nichols et al., 1990 31 15 (48) 55 PVB or BEP
(13-14) +5inlO
Toner et al., 1991 32 8 (25) (1-70) (CT + S)
Horwich et al. 11 8 (73) 55 (12- 113) CT + S (see text)
(current series)
Total 136 54 (40)
CT = Chemotherapy; RT = Radiotherapy; S = Surgery; (a) = one patient alive
with disease; (b) = two patients alive with disease; VAB= cyclophosphamide,
cisplatin, vinblastine, bleomycin and doxorubicin; VAB-VV = cyclophosphamide,
vinblastine, actinomycin D, bleomycin, cisplatin, alternating with VP16-213 and
vincristine; PVB = cisplatin, vinblastine and bleomycin; BEP = bleomycin, etoposide
and cisplatin.MEDIASTINAL GERM CELL TUMOURS 1101
seminoma, though excellent results are found with cisplatin-
based combination chemotherapy, and for smaller tumours
radiotherapy alone is effective (Table IV). More intensive
regimens may provide a good chance of successful salvage
should relapse occur after carboplatin chemotherapy (Hor-
wich, 1990). As reported in this and other studies (Schultz et
al., 1989), a proportion of patients will continue to have a
persistent soft tissue mass evident on CXR or CT scanning
after attaining a complete remission. Whether the addition of
mediastinal radiotherapy would improve the relapse free sur-
vival is not established.
All the patients with teratoma in this study had very bulky
mediastinal disease and all but one had high serum tumour
markers, factors which are known to predict for a poor
prognosis (Mead et al., 1992). It is possible that the prog-
nosis for mediastinal teratoma is not independent of the
prognostic factors identified for malignant testicular germ cell
tumours.
The results of treatment for patients with malignant
teratoma of the mediastinum remain less satisfactory. Studies
reported since 1985 show a range of overall survival from
21% to 63% (Horwich & Peckham, 1986; McLeod et al.,
1988; Kiffer & Sandeman, 1989; Logothetis et al., 1986;
Giaccone et al., 1991; Kersh et al., 1987; Parker et al., 1986;
Nichols et al., 1990a; Toner et al., 1991) (Table V). Previous
reports were even more gloomy (Fuen et al., 1980; Israel et
al., 1985). In these studies many different types of
chemotherapy were used; a proportion of patients in some
studies did not receive platinum-based chemotherapy, some
patients received radiotherapy only and there was not a
consistent policy of surgical resection for residual masses.
The overall survival of 73% in our study is encouraging and
suggests that experience with platinum based chemotherapy,
in conjunction with surgical resection of residual mediastinal
masses, may be leading to an improved outlook for these
patients.
It is recommended that chemotherapy for mediastinal
seminoma be based on carboplatin or cisplatinum possibly as
single agents. Because patients with non-seminomatous germ
cell tumours of the mediastinum have an adverse prognosis
continued use of more intensive cisplatinum based combina-
tion chemotherapy is advised.
This work was supported by grants from the Cancer Research
Campaign and The Bob Champion Cancer Trust.
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